Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01537159 · ClinicalTrials.gov registry record
MRI Assessment of Leukemia Response to Therapy
A clinical trial, sponsored by OHSU Knight Cancer Institute.
- Completed
- Registry status
- 23
- Enrollment target
NCT01537159 is a clinical trial that has completed, run by OHSU Knight Cancer Institute. The registered enrollment target is 23 participants.
The verdict
NCT01537159 has completed, sponsored by OHSU Knight Cancer Institute.
- COMPLETED
- Registry status
- 23 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate if a type of magnetic resonance imaging (MRI) scan of the bone marrow before the start of standard chemotherapy can predict complete remission of leukemia patients after the therapy. This type of MRI scan, called dynamic contrast-enhanced MRI (DCE-MRI), measures bone marrow blood flow. For those patients who do not achieve complete remission status after initial therapy and will be treated with additional therapy, the investigators are also interested in determining if the second MRI exam before the additional therapy can predict complete remission. If successfully tested, the MRI exam may be used in the future to help with early identification of patients who are unlikely to respond to standard chemotherapy. This will allow for a personalized therapeutic plan to be developed for these patients at an early stage and prevent them from being exposed to toxic and ineffective therapies.
Interventions
- DEVICE 3 Tesla (3T) Siemens Total imaging matrix (TIM) Trio whole-body system
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2012-05 |
| Est. Completion | 2018-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01537159
The ClinicalTrials.gov registry entry for NCT01537159 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OHSU Knight Cancer Institute, which has 211 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 3 Tesla (3T) Siemens Total imaging matrix (TIM) Trio whole-body system is the first listed.
NCT01537159 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01537159 about?
NCT01537159 is a clinical study titled "MRI Assessment of Leukemia Response to Therapy". The purpose of this study is to investigate if a type of magnetic resonance imaging (MRI) scan of the bone marrow before the start of standard chemotherapy can predict complete remission of leukemia patients after the therapy. This type of MRI scan, called dynamic contrast-enhanced MRI (DCE-MRI), me...
What is the current status of trial NCT01537159?
This trial is currently completed. The enrollment target is 23 participants. The study started on 2012-05. Estimated completion is 2018-12-31.
What interventions are being tested in trial NCT01537159?
The interventions under investigation include: 3 Tesla (3T) Siemens Total imaging matrix (TIM) Trio whole-body system (DEVICE).
Who is sponsoring clinical trial NCT01537159?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.